T1 mapping to characterize heart tissue in common heart diseases
The Landscape of T1 Mapping for Disease Profiling in a Real-World Cohort
This project tests whether T1 mapping MRI scans, including dye-free native T1, can define normal and disease-specific heart tissue values for adults with various heart conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Sex | All |
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT07354646 on ClinicalTrials.gov |
What this trial studies
This observational, single-center study will collect cardiac MRI T1 mapping scans from adults with guideline-confirmed myocardial conditions (MI, HCM, DCM, myocarditis, arrhythmogenic cardiomyopathy and other listed diagnoses) at Fuwai Hospital. Imaging will include native (non-contrast) T1 measurements and contrast-enhanced scans to derive extracellular volume (ECV). Investigators will analyze images together with clinical records to create disease-specific reference ranges and to compare the diagnostic performance of native T1 versus ECV. The aim is to produce a real-world spectrum of T1 values that clinicians can apply when interpreting advanced cardiac MRI.
Who should consider this trial
Good fit: Adults (≥18 years) with guideline-confirmed myocardial diseases such as MI, hypertrophic, dilated, arrhythmogenic cardiomyopathies, myocarditis, infiltrative or other cardiac conditions who can undergo cardiac MRI are ideal candidates.
Not a fit: Patients who cannot undergo MRI (for example due to incompatible implants), who are under 18, or whose cardiac condition is not represented in the enrolled disease categories may not receive benefit.
Why it matters
Potential benefit: If successful, clinicians could use clear, disease-specific T1 reference ranges—and possibly dye-free native T1—to diagnose and monitor heart diseases more easily and with less reliance on contrast agents.
How similar studies have performed: T1 mapping and ECV have demonstrated diagnostic value in prior research for many cardiomyopathies, but large real-world reference datasets and direct comparisons of native T1 versus ECV across diverse diseases remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines. 2. Specific disease categories include: * Cardiomyopathies (HCM, DCM, RCM, ACM) * Infiltrative disorders (cardiac amyloidosis, Fabry disease) * Inflammatory conditions (acute/chronic myocarditis) * Ischemic heart disease (acute/chronic MI) * Valvular heart disease (aortic stenosis) * Arrhythmic conditions (atrial fibrillation) * Metabolic disorders (iron-overload) * Neoplastic conditions (cardiac tumors) * Congenital heart disease * Post-transplant evaluation 3. All diagnoses must be confirmed using established guideline-based criteria: * Echocardiographic parameters meeting disease-specific cutoffs * Cardiac MRI findings consistent with current consensus criteria * Laboratory biomarkers supporting respective diagnoses * Histopathological confirmation when clinically indicated Exclusion Criteria: * Presence of multiple cardiomyopathy diseases or risk factors simultaneously * Contraindications to CMR examination * Poor image quality precluding accurate T1 mapping analysis * Incomplete clinical data for definitive diagnosis confirmation * Pregnancy or lactation * Inability to provide informed consent
Where this trial is running
Beijing, Beijing Municipality
- Fuwai Hospital, Chinese Academy of Medical Sciences — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Huaying Zhang, Doctor
- Email: zhy_dreamer@163.com
- Phone: 86 13695310578
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.